NBI 34041

Drug Profile

NBI 34041

Alternative Names: SB 723620

Latest Information Update: 11 Dec 2003

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Developer GlaxoSmithKline
  • Class Acenaphthenes; Antidepressants; Antispasmodics; Anxiolytics; Irritable bowel syndrome therapies
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 11 Dec 2003 Discontinued - Phase-I for Irritable bowel syndrome in United Kingdom (unspecified route)
  • 11 Dec 2003 Discontinued - Phase-I for Depression in United Kingdom (unspecified route)
  • 11 Dec 2003 Discontinued - Phase-I for Anxiety disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top